The U.K.'s Joint Committee on Vaccination and Immunization (JCVI) is revising its stance on Novartis' meningitis B vaccine Bexsero. The jab, originally left off Britain's routine vaccination schedule, has gained the JCVI's nod, supplying a needed boost for the Swiss company's flailing vaccine unit.
Researchers have shown in early tests that a nasal vaccine for West Nile virus is effective in mice after two doses as opposed to the traditional three for other vaccines. Currently, no vaccine for the disease is available for humans, despite its recent spread in the U.S. and Canada.
It turns out that Germany will not be the only country facing a shortage of GlaxoSmithKline's chickenpox vaccines. While healthcare providers there have already been given a heads up to prepare for rationing, the company says deliveries worldwide will be affected.
After launching a subsidiary in December that will focus on vaccines, Astellas Pharma is showing that it's serious about becoming a player in the vaccines sector.
Last year, the FDA came down hard on a Sanofi Pasteur plant in Toronto. The ensuing trouble triggered serious supply problems--and, in turn, a shortage of childhood vaccines in the U.S.
Craig Venter has revealed more details of his plans for printable vaccines and antibiotics in an interview with The Guardian.
Getting vaccines to stay in mucosal membranes long enough to trigger an immune response can be tricky. Engineers have now developed nanoparticles to carry vaccines to the mucosal surface in the lungs, protecting them long enough to provoke an immune response.
Analysts predicted Merck shingles vaccine Zostavax would be a blockbuster when it was first released in 2006. But Merck quickly ran into manufacturing and supply issues, putting a damper on sales and expectations. A $1 billion upgrade has put its production problems behind it and posed Merck for expansion even as demand for Zostavax has jumped.
Novartis' Bexsero may be the only vaccine approved for life-threatening meningitis B, but that wasn't enough to convince the U.K.'s Joint Committee on Vaccination and Immunisation to add it to Britain's routine vaccination schedule.
One reason Pfizer snapped up Wyeth in 2009: Its Prevnar/Prevenar vaccine franchise. Now, the latest version of the pneumococcal shot is Pfizer's fourth-biggest seller, with $3.72 billion in 2012 revenues. But Pfizer wants even more.